Todd Durniak to demonstrate the Dario solution during the breakout session “The Measured Life: Tracking from Head to Toe”
CAESAREA, Israel, September 30, 2015, OTCQB, DRIO, /PRNewswire/ —
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario™ Diabetes Management Solution, today announced that its Executive Vice President of U.S. Operations, Todd Durniak, will deliver a demonstration of the Dario Solution at Health 2.0’s 9th Annual Fall Conferencein Santa Clara, California on Wednesday, October 7, 2015 at 10:45 am PT.
Mr. Durniak will give a live demonstration of the Dario during the breakout session titled, “The Measured Life: Tracking from Head to Toe.” The Dario will be one of five innovative products to be demonstrated during the session.
According to Health 2.0, the session will focus on the following:
- “Real-time data has been easier to obtain as new technology is developed to track your body. Continuous tracking has allowed for a more precise measurement of your health sent directly to your doctors. These additional insights from tracking tools have helped physicians and consumers gain a better understanding of people’s health and lifestyle. With the hundreds of trackers and monitors in the health technology market today, this session will showcase the ones that are beautifully designed and most effective.”
“This is an ideal time for us to present the Dario at Health 2.0’s Silicon Valley conference, as the Dario solution leverages the best in smart phone technology to meet healthcare needs. We continue to increase our market awareness activities in the U.S., in anticipation of our expected market approval and launch of the Dario Diabetes Management Solution in America,” stated LabStyle President and Chief Executive Officer Erez Raphael.
About Health 2.0
Health 2.0 is the premiere showcase and catalyst for the advancement of new health technologies. Through a global series of conferences, developer competitions, and leading market intelligence, Health 2.0 drives the innovation and collaboration necessary to transform health and health care. In addition to its flagship event held in the Bay Area each Fall, Health 2.0 hosts events around the world including in Europe,Latin America and India, and for 2015 Korea and Japan.
About LabStyle Innovations
LabStyle Innovations Corp. (OTCQB: DRIO) develops and commercializes patent-pending technology providing consumers with laboratory-testing capabilities using smart mobile devices. LabStyle’s flagship product is the Dario™ personalized smart meter. Dario™ received CE mark certification in September 2013 and began a world rollout in select countries in December 2013. LabStyle filed a Premarket Notification Application, also known as a 510(k), with the US Food and Drug Administration (FDA) for the Dario™ smart meter (Dario™ Blood Glucose Monitoring System) in December 2013. LabStyle is pursuing patent applications in multiple areas covering the specific processes related to blood glucose level measurement as well as more general methods of rapid tests of body fluids using mobile devices and cloud-based services. For more information: http://www.mydario.com and http://mydario.investorroom.com the content of which is not part of this press release.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of LabStyle Innovations Corp. (the “Company”) related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. For example, we are using forward looking statements in this press release when we discuss the Dario solution utilizing the best smart phone technology to meet healthcare needs and our anticipated market approval and product launch in America. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company’s commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.